What is COMPASS Pathways?
COMPASS Pathways plc (Nasdaq: CMPS) is a mental health care company dedicated to accelerating patient access to evidence-based innovation in mental health. The firm is pioneering a new model of psilocybin therapy, utilizing its proprietary synthetic formulation, COMP360, administered alongside specialized psychological support. By focusing on patients who have not responded to conventional treatments, COMPASS Pathways occupies a critical niche in the biotechnology and psychiatric care landscape, aiming to transform the standard of care for treatment-resistant conditions.
How much funding has COMPASS Pathways raised?
COMPASS Pathways has raised a total of $578.5M across 5 funding rounds:
Series A
$35.5M
Series B
$80M
Stock Offering
$128M
Debt
$50M
Other Financing Round
$285M
Series A (2018): $35.5M, investors not publicly disclosed
Series B (2020): $80M led by McQuade Center for Strategic Research and Development, Perceptive Advisors, Camden Partners Nexus, Founders Fund, ATAI Life Sciences, Soleus Capital, Skyviews Life Science, and Able Partners
Stock Issuance/Offering (2020): $128M, investors not publicly disclosed
Debt (2023): $50M featuring Hercules Capital
Other Financing Round (2023): $285M backed by Aisling Capital, TCG Crossover, Logos Capital Partners Sa rl, and Vivo Capital
Key Investors in COMPASS Pathways
Aisling Capital
Aisling Capital is a leading investment firm specializing in companies that develop and commercialize innovative healthcare products, services, and technologies, with a focus on biopharmaceutical development and neuroscience.
TCG Crossover
TCG Crossover is a science-driven investment firm focused on advancing disruptive medicines and supporting innovators in the pharmaceutical and biotechnology sectors.
Perceptive Advisors
Perceptive Advisors is a New York-based investment firm managing significant assets, dedicated to funding innovative healthcare and life sciences technologies.
What's next for COMPASS Pathways?
With the recent infusion of $285M, COMPASS Pathways is well-positioned to accelerate its clinical development programs and expand its operational footprint. The strategic focus will likely remain on navigating regulatory pathways for COMP360 while scaling the infrastructure required for broader therapeutic delivery. As the company transitions into a more mature commercial phase, the emphasis will shift toward long-term sustainability and the integration of its mental health solutions into mainstream healthcare systems, supported by a diverse syndicate of life sciences investors.
See full COMPASS Pathways company page
